Adverse Effects Assessment

The adverse-event pattern was consistent with the known GLP-1 receptor agonist safety profile, especially gastrointestinal symptoms. General safety questions and spontaneous reporting can underestimate adverse effects compared with structured instruments. Only one of the 35 quantitative reports assessed a potential adverse effect quantitatively. Before the M-SET, no targeted structured measure existed for MDMA-assisted psychotherapy side effects. No other quantitative study measured and compared adverse-effect outcomes across arms. Clinical trials in patients relied largely on spontaneous side-effect reporting with limited structured assessment beyond suicidality and physiological measures. The absence of measured adverse effects should not be interpreted as evidence that harms do not exist. Most MDMA-assisted psychotherapy studies had not systematically assessed safety and tolerability. Blueprint intends to assess intervention safety and efficacy before recommending them broadly. The single quantitative adverse-effect assessment found no detected adverse effect. The program plans to share findings after enough data is gathered on benefits and safety profiles. No treatment-related…